HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Teruhiko Mizumoto Selected Research

camostat

8/2021A serine protease inhibitor camostat mesilate prevents podocyte apoptosis and attenuates podocyte injury in metabolic syndrome model rats.
10/2016A serine protease inhibitor attenuates aldosterone-induced kidney injuries via the suppression of plasmin activity.
2/2016Combination therapy with renin-angiotensin-aldosterone system inhibitor telmisartan and serine protease inhibitor camostat mesilate provides further renoprotection in a rat chronic kidney disease model.
1/2015The serine protease inhibitor camostat mesilate attenuates the progression of chronic kidney disease through its antioxidant effects.
7/2013The antifibrotic effect of a serine protease inhibitor in the kidney.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Teruhiko Mizumoto Research Topics

Disease

5Fibrosis (Cirrhosis)
10/2016 - 10/2012
2Acute Kidney Injury (Acute Renal Failure)
01/2022 - 11/2018
2Wounds and Injuries (Trauma)
08/2021 - 10/2016
2Hypertension (High Blood Pressure)
08/2021 - 10/2012
2Proteinuria
08/2021 - 10/2012
2Ureteral Obstruction
10/2016 - 07/2013
2Chronic Renal Insufficiency
02/2016 - 01/2015
1Reperfusion Injury
01/2022
1Ischemia
01/2022
1Rodent Diseases
08/2021
1Metabolic Syndrome (Dysmetabolic Syndrome X)
08/2021
1Albuminuria
11/2020
1Disease Progression
11/2020
1Premature Aging
01/2020
1Infections
11/2018
1Body Weight (Weight, Body)
11/2018
1Neoplasms (Cancer)
11/2018
1Kidney Diseases (Kidney Disease)
10/2016
1Insulin Resistance
03/2014
1Chronic Kidney Failure (Chronic Renal Failure)
10/2012
1Hypertrophy
10/2012

Drug/Important Bio-Agent (IBA)

7Serine Proteinase Inhibitors (Serine Protease Inhibitors)IBA
08/2021 - 10/2012
5camostatIBA
08/2021 - 07/2013
3Serine Proteases (Serine Protease)IBA
08/2021 - 03/2014
2CreatinineIBA
01/2022 - 10/2012
2nephrinIBA
11/2020 - 10/2012
2SaltsIBA
10/2016 - 10/2012
2AdenineFDA LinkGeneric
02/2016 - 01/2015
2Proteins (Proteins, Gene)FDA Link
01/2015 - 10/2012
2CollagenIBA
07/2013 - 10/2012
1Adenosine Triphosphate (ATP)IBA
01/2022
1KUS121IBA
01/2022
1Valosin Containing ProteinIBA
01/2022
1Lipocalin-2IBA
01/2022
1RNA (Ribonucleic Acid)IBA
11/2020
1Drinking WaterIBA
11/2018
1Anti-Bacterial Agents (Antibiotics)IBA
11/2018
1Tetracycline (Achromycin)FDA LinkGeneric
11/2018
1Pharmaceutical PreparationsIBA
11/2018
1Doxycycline (Periostat)FDA LinkGeneric
11/2018
1Cisplatin (Platino)FDA LinkGeneric
11/2018
1AldosteroneIBA
10/2016
1FibrinolysinFDA Link
10/2016
1Telmisartan (Micardis)FDA Link
02/2016
1AntioxidantsIBA
01/2015
1NADPH Oxidases (NAD(P)H oxidase)IBA
01/2015
1Messenger RNA (mRNA)IBA
01/2015
1prostasinIBA
03/2014
1Toll-Like Receptor 4IBA
03/2014
1Transforming Growth Factors (Transforming Growth Factor)IBA
07/2013
1Plasminogen Activators (Plasminogen Activator)IBA
07/2013
1Hydroxyproline (4 Hydroxyproline)IBA
07/2013
1Matrix Metalloproteinase 2 (Gelatinase A)IBA
07/2013
1Connective Tissue Growth FactorIBA
07/2013

Therapy/Procedure

1Renal Dialysis (Hemodialysis)
01/2020
1Therapeutics
02/2016
1Nephrectomy
10/2012